Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 11:20:00 2024-07-12 am EDT 5-day change 1st Jan Change
980.3 DKK +1.34% Intraday chart for Novo Nordisk A/S +0.65% +40.42%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market RE
Ozempic linked with lower dementia risk, nicotine use, British study finds RE
European Equities Close Higher in Friday Trading; Unilever to Cut 3,200 European Jobs MT
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says RE
Novo Nordisk's Ozempic Reduces Dementia and Cognitive Risks, Oxford Study Says MT
NOVO NORDISK : Buy rating from Deutsche Bank ZD
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup DJ
European Equities Close Higher Thursday; UK GDP Grows More Than Expected MT
Global markets live: Tesla, Citigroup, BP, Novo Nordisk, JPMorgan... Our Logo
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading MT
Novo Nordisk Partners with Bio Farma to Package Insulin in Indonesia MT
Novo Nordisk Partners with Bio Farma to Package Insulin in Indonesia MT
Pfizer moves forward with once-daily weight loss drug RE
Novo Nordisk Gets Complete Response Letter from US FDA for Insulin Icodec Application MT
NOVO NORDISK : Goldman Sachs reiterates its Buy rating ZD
NOVO NORDISK : JP Morgan reaffirms its Buy rating ZD
Gerresheimer core profit meets forecast on weight-loss drug deals pipeline RE
Novo Nordisk: FDA applications for icodec CF
Novo Nordisk Receives Additional Information Request from US FDA for Insulin Icodec MT
Novo Nordisk Signs MoU with Indonesia's Bio Farma for Insulin Packaging MT
US FDA declines to approve Novo Nordisk's weekly insulin RE
Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec CI
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices RE
SANDERS SAYS HE IS CURRENTLY FOCUSED ON NOVO NORDISK BUT WILL 'C… RE
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
980.3 DKK
Average target price
956.5 DKK
Spread / Average Target
-2.43%
Consensus